<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60371">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01881035</url>
  </required_header>
  <id_info>
    <org_study_id>VCH Heart Station 10</org_study_id>
    <secondary_id>TreatDialRDN (II)</secondary_id>
    <nct_id>NCT01881035</nct_id>
  </id_info>
  <brief_title>Treatment of Resistant Hypertension by Renal Sympathetic Denervation in Patients Undergoing Dialysis Therapy</brief_title>
  <acronym>TreatDialRDN</acronym>
  <official_title>Treatment of Resistant Hypertension by Renal Sympathetic Denervation in Patients Undergoing Dialysis Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oulu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Satakunta Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Finland Hospital District</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vaasa Central Hospital, Vaasa, Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <authority>Finland: Valvira - National Supervisory Authority for Welfare and Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to investigate the efficacy of renal nerve denervation in treating
      drug-resistant hypertension  in patients with end stage renal disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Drug resistant hypertension is very common in end stage renal disease treated by dialysis.
      The prevalence of hypertension has been evaluated to be over 50% and up 80%. In this patient
      group mortality figures are high because of cardiovascular diseases which are complications
      of hypertension. Renal nerve denervation is a new intervention to treat hypertension. By
      applying radiofrequency pulses to the renal arteries, the nerves in the vascular wall
      (adventitia layer) can be denervated. This causes reduction of renal sympathetic afferent
      and efferent activity and blood pressure can be decreased. The technique and its efficacy in
      end stage renal disease has not been systematically studied. There are case reports which
      have showed promising responses to denervation. In the present study 30 patients over 18
      years are planned undergo renal denervation if the medical treatment (three different drugs
      including diuretics) has failed to decrease blood pressure sufficiently(160/100mmHg). The
      failure of medical treatment will be documented by ambulatory blood pressure measurements.
      After renal nerve denervation a two year follow-up of patients with ambulatory blood
      pressure measurements will be organized. The blood pressures before and after denervation
      are compared and the quality of life of the patients is evaluated by questionnaires.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Comparison of blood pressures before and after intervention</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>12-lead ECG changes</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hypertension Secondary to Renal Disease</condition>
  <arm_group>
    <arm_group_label>Renal nerve denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal nerve denervation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Renal nerve denervation</intervention_name>
    <description>Renal nerve denervation is performed by catheter ablation of renal arteries influencing the sympathetic nerves.</description>
    <arm_group_label>Renal nerve denervation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with end stage renal disease and drug-resistant blood pressure.

        Exclusion Criteria:

          -  pregnancy

          -  secondary hypertension

          -  unstable coronary artery disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Juhani Koistinen, MD</last_name>
    <phone>+35863231111</phone>
    <email>juhani.koistinen@vshp.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vaasa Central Hospital</name>
      <address>
        <city>Vaasa</city>
        <zip>65130</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juhani Koistinen, MD</last_name>
      <phone>+35863231111</phone>
      <email>juhani.koistinen@vshp.fi</email>
    </contact>
    <contact_backup>
      <last_name>P채ivi Pietil채-Effati, MD</last_name>
      <phone>+35863231111</phone>
      <email>paivi.pietila-effati@vshp.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Juhani Koistinen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>P채ivi Pietil채-Effati, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 27, 2013</lastchanged_date>
  <firstreceived_date>June 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Turku University Hospital</investigator_affiliation>
    <investigator_full_name>Juhani Koistinen</investigator_full_name>
    <investigator_title>Professor in Medicine Turku University</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>End stage renal disease</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Hypertension, Renal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
